The Creso Pharma Ltd (ASX: CPH) share price has falling 6.5% after a heavily oversubscribed placement to advance its psychedelics trials
The post Here’s why the Creso Pharma (ASX:CPH) share price is falling 7% appeared first on The Motley Fool Australia. –
The funds raised will be deployed to undertake psychedelic clinical trials upon the completion of the company’s Halucenex acquisition. Halucenex is a life sciences company focused on researching novel psychedelic compounds and developing and licensing products for the emerging global psychedelic medicines market.
Creso share price falls on capital raise
The Creso share price is on the slide today after the company advised it has secured firm commitments from institutional, professional and sophisticated investors to raise up to A$18 million. The funds will be raised via the issue of approximately 94.7 million new shares at an issue price of 19 cents per share.
The company notes that the placement was heavily oversubscribed and strongly supported by a range of local and international groups including leading Australian businessman John Langley Hancock, S3 Consortium Holdings Pty Ltd and independent global fund manager L1 Global Master Opportunities Fund, among others.
Funds to advance clinical trials and nutraceutical offerings
Creso Pharma has recently focused its attention on its “transformational” psychedelics acquisition, Halucenex. Its phase II and phase III clinical trials will explore the efficacy of psychedelic molecules on a range of mental health conditions, such as depression and post-traumatic stress disorder, and open up another potentially lucrative vertical.
The company will also deploy funds to expand its current nutraceutical offerings via its wholly-owned Canadian subsidiary, Mernova Medicinal Inc. On 19 March, Mernova received three purchase orders valued at C$177,122.40 (A$183,019.551). These included the company’s first purchase order for its pre-roll joint range, sold under the Ritual Sticks brand.
Non-executive chair Adam Blumenthal was pleased with the strong interest in the placement and believes it will position Creso to explore greater opportunities in the near-term. He said:
The Placement was very well bid and leaves Creso Pharma well funded to progress a number of near term revenue generating initiatives. Key short-term focus will include finalising the acquisition of Halucenex and undertaking clinical trials. Importantly, the acquisition provides the Company with access to another lucrative vertical and potential revenue stream. We will also be ramping up our nutraceutical division and preparing for the anticipated legalisation of cannabis in the US through our Canadian operations.
The Creso share price has increased by more than 250% over the past 12 months.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Japan’s $103 million pot stock hypocrisy unmasked
- Creso Pharma (ASX:CPH) share price lower despite cannabis sales update
- Why the Creso Pharma (ASX:CPH) share price is rocketing 16% higher today
- Creso Pharma (ASX:CPH) to commence phase II clinical trials
- How Mexico could turbocharge ASX cannabis shares
Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.